Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Post-Market Trading 11-25 19:30:09 EST

0.5526

+0.0226

+4.26%

盘后0.5500

-0.0026-0.47%

18:53 EST

High0.5587	Low0.5301	Vol1.30M
Open0.5433	D1 Closing0.5300	Amplitude5.40%
Mkt Cap57.36M	Tradable Cap33.96M	Total Shares103.80M
T/O709.83K	T/O Rate2.11%	Tradable Shares61.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":0.5526,"timestamp":1732568400000,"preClose":0.53,"halted":0,"volume":1299535,"hourTrading":{"tag":"盘后","latestPrice":0.55,"preClose":0.5526,"latestTime":"18:53 EST","volume":9714,"amount":5366.5473843,"timestamp":1732578831148},"delay":0,"floatShares":61454000,"shares":103796406,"eps":-0.489086,"marketStatus":"Post-Market Trading","change":0.0226,"latestTime":"11-25 19:30:09 EST","open":0.5433,"high":0.5587,"low":0.5301,"amount":709829.4606114,"amplitude":0.053962,"askPrice":0.5625,"askSize":2000,"bidPrice":0.5448,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.489086,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732582800000},"marketStatusCode":4,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":0.53,"preHourTrading":{"tag":"盘前","latestPrice":0.549,"preClose":0.53,"latestTime":"09:25 EST","volume":35670,"amount":19129.260981000003,"timestamp":1732544710189},"postHourTrading":{"tag":"盘后","latestPrice":0.55,"preClose":0.5526,"latestTime":"18:53 EST","volume":9714,"amount":5366.5473843,"timestamp":1732578831148},"volumeRatio":1.265958},"requestUrl":"/m/hq/s/UNCY/wiki","defaultTab":"wiki","newsList":[{"id":"2485261147","title":"Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485261147?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:49","pubTimestamp":1732286940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 09:49 ET (14:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","UNCY"],"gpt_icon":0},{"id":"2485620774","title":"Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2485620774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485620774?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:00","pubTimestamp":1732190400,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Nov.  21, 2024  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985083/0/en/Unicycive-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-Including-a-Fireside-Chat-at-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4539","BK4139","HCSG","UNCY","LENZ"],"gpt_icon":0},{"id":"2483893053","title":"Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483893053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483893053?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:35","pubTimestamp":1731602134,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $2.00. Jas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-market-position-and-fda-milestone-propel-unicycive-therapeutics-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-market-position-and-fda-milestone-propel-unicycive-therapeutics-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","UNCY"],"gpt_icon":0},{"id":"2483799000","title":"BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483799000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483799000?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:32","pubTimestamp":1731504752,"startTime":"0","endTime":"0","summary":"BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business UpdateNov 13  - Unicycive Therapeutics Inc UNCY.O:UNICYCIVE ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE: QTRLY LOSS PER SHARE $0.05Q3 EARNINGS PER SHARE VIEW $-0.15 -- LSEG IBES DATASource text: nGNX5cJmcNFurther company coverage: UNCY.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"gpt_icon":0},{"id":"2483041001","title":"Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483041001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483041001?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:35","pubTimestamp":1731501351,"startTime":"0","endTime":"0","summary":"“We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-reports-q3-eps-13c-consensus-15c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-reports-q3-eps-13c-consensus-15c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","LENZ"],"gpt_icon":0},{"id":"2483006741","title":"Unicycive Therapeutics Q3 Income From Operations USD -6.251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483006741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483006741?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX813FA8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2483747006","title":"Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483747006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483747006?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2483099040","title":"Unicycive Therapeutics Inc  Q3 Shr View $-0.15 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2483099040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483099040?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"gpt_icon":0},{"id":"2483009314","title":"Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009314","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483009314?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":"-- OLC New Drug Application  Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025--. -- Commercial Planning in Progress for 2025 Launch --. \"We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application for oxylanthanum carbonate  which may result in the potential approval of our first drug in 2025,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"If approved, we believe OLC's high potency and low pill burden would provide a best-in-class option for patients with chronic kidney disease  on dialysis who have hyperphosphatemia and face adherence challenges with current treatment regimens. With the NDA acceptance now behind us, we are actively preparing to commercialize OLC with the goal of bringing this innovative new treatment to market in the second half of 2025.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","UNCY","UNI.USD.HKCC","BK4232","UNI.USD.CC"],"gpt_icon":0},{"id":"2482785481","title":"Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482785481","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482785481?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:47","pubTimestamp":1731329225,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.Unicycive shares were nearly 3% higher in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","UNCY","BK4139"],"gpt_icon":0},{"id":"2482178397","title":"Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482178397","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482178397?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:31","pubTimestamp":1731328260,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics said the Food and Drug Administration accepted its application seeking approval of its lead drug candidate as a treatment for an electrolyte disorder related to kidney disease.Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target action date of June 28, 2025 for the application.The Los Altos, Calif., clinical-stage biotechnology company said oxylanthanum carbonate, if approved, would lower the pill burden in terms of the number and size per dose for patients with hyperphosphatemia, a condition involving too much phosphate in the blood that occurs in nearly all patients with end-stage renal disease.Unicycive said it was preparing to commercialize and launch the drug in the second half of 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"gpt_icon":0},{"id":"2482788135","title":"Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2482788135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482788135?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:07","pubTimestamp":1731326829,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for Oxylanthan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-u-s-fda-acceptane-for-nda-for-olc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-u-s-fda-acceptane-for-nda-for-olc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","UNCY","LENZ"],"gpt_icon":0},{"id":"2482200905","title":"Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200905?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC22JCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UNCY","BK4539"],"gpt_icon":0},{"id":"2482200476","title":"Unicycive Therapeutics Inc - Preparing for 2025 Commercial Launch of Olc","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200476?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC22JCV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","UNCY","BK4139"],"gpt_icon":0},{"id":"2482004752","title":"Unicycive Therapeutics Inc - FDA Sets Pdufa Action Date of June 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2482004752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482004752?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC22JCV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"gpt_icon":0},{"id":"2482200164","title":"Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200164","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200164?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":"– FDA sets PDUFA Action Date of June 28, 2025 – Company Preparing for 2025 Commercial Launch – LOS ALTOS, Calif., Nov.  11, 2024  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978178/0/en/Unicycive-Therapeutics-Announces-U-S-FDA-Acceptance-of-the-New-Drug-Application-NDA-for-Oxylanthanum-Carbonate-OLC-for-the-Treatment-of-Hyperphosphatemia-in-Patients-with-Chronic-K.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","IE00BKVL7J92.USD","BK4006","LU0170899867.USD","LENZ","LU1363072403.SGD","BK4539","LU0267386448.USD","BK4139","UNCY","CMC","LU0971096721.USD","LU0149725797.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2478060191","title":"Unicycive presents on development progress of oxylanthanum carbonate","url":"https://stock-news.laohu8.com/highlight/detail?id=2478060191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478060191?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:21","pubTimestamp":1730114464,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that high...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-presents-on-development-progress-of-oxylanthanum-carbonate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-presents-on-development-progress-of-oxylanthanum-carbonate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UNCY","BK4539"],"gpt_icon":0},{"id":"2478105183","title":"Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478105183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478105183?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:03","pubTimestamp":1730113380,"startTime":"0","endTime":"0","summary":"– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 –  LOS ALTOS, Calif., Oct.  28, 2024  (GLOBE NEWSWIR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2969951/0/en/Unicycive-Therapeutics-Delivers-Multiple-Poster-Presentations-Highlighting-Development-Progress-on-Oxylanthanum-Carbonate-OLC-and-UNI-494-at-the-American-Society-of-Nephrology-ASN-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4023","BK4218","PD","BK4117","BK4181","PK","AFG","BK4539","LU2065732104.USD","PRGS","BK4107","UNCY","LENZ","LU1169590202.USD","BK4183","LU1169589451.USD","BK4139","BK4097"],"gpt_icon":0},{"id":"2475625991","title":"Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2475625991","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475625991?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:15","pubTimestamp":1729077311,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ) is possibly approaching a major achievement in its business, so we would...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/unicycive-therapeutics-inc-nasdaquncy-is-breakeven-near-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4585","BK4539","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","UNCY","BK4588","NQmain",".IXIC","IE00BKPKM429.USD","QID","SQQQ","MNQmain","PSQ","LU2210149790.SGD","QLD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","TQQQ"],"gpt_icon":1},{"id":"2475735245","title":"Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475735245","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475735245?lang=en_us&edition=fundamental","pubTime":"2024-10-14 19:03","pubTimestamp":1728903780,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Oct. 14, 2024  -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced that a poster presentation on oxylanthanum carbonate  was selected for a Late-Breaker session at the American Society of Nephrology  Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA.Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia. Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research&Medical Affairs, U.S. Renal Care","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GldtEVoS99x87WCmslYrsg--~B/aD00ODQ7dz04MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3692a6cc1430d6e658d9a99c4222d3c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GldtEVoS99x87WCmslYrsg--~B/aD00ODQ7dz04MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3692a6cc1430d6e658d9a99c4222d3c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unicycive-therapeutics-announces-breaker-poster-110300097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODD","BK4023","LENZ","BK4107","BK4117","LU1169590202.USD","BK4139","UNCY","AFG","PD","LU1169589451.USD","BK4539","BK4183"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.1522},{"period":"1month","weight":0.3048},{"period":"3month","weight":0.4021},{"period":"6month","weight":-0.4397},{"period":"1year","weight":-0.0862},{"period":"ytd","weight":-0.3892}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.066071},{"month":2,"riseRate":0.666667,"avgChangeRate":0.127697},{"month":3,"riseRate":0.333333,"avgChangeRate":0.996651},{"month":4,"riseRate":0,"avgChangeRate":-0.298132},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.055066},{"month":6,"riseRate":0,"avgChangeRate":-0.179728},{"month":7,"riseRate":0,"avgChangeRate":-0.107364},{"month":8,"riseRate":0.25,"avgChangeRate":-0.144614},{"month":9,"riseRate":0.5,"avgChangeRate":0.038379},{"month":10,"riseRate":0.75,"avgChangeRate":0.041357},{"month":11,"riseRate":0.25,"avgChangeRate":-0.088937},{"month":12,"riseRate":0.333333,"avgChangeRate":0.149314}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}